{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Edema+Secondary+to+Retinal+Vein+Occlusion", "query": { "condition": "Macular Edema Secondary to Retinal Vein Occlusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Edema+Secondary+to+Retinal+Vein+Occlusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T04:07:40.281Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03802630", "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2019-07-02", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03802630" }, { "nct_id": "NCT01028248", "title": "Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Central Retinal Vein Occlusion" ], "interventions": [ { "name": "Ranibizumab (Lucentis)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Retina Consultants", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2010-01", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-12-12", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 3, "location_summary": "Bakersfield, California • Santa Barbara, California • Santa Maria, California", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01028248" }, { "nct_id": "NCT01581151", "title": "Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Retinal Vein Occlusion" ], "interventions": [ { "name": "Dexamethasone intravitreal implant", "type": "DRUG" }, { "name": "Monthly Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Burke, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2011-09", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-02-20", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581151" }, { "nct_id": "NCT00943072", "title": "Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema Secondary to Central Retinal Vein Occlusion" ], "interventions": [ { "name": "VEGF Trap-Eye 2.0mg", "type": "BIOLOGICAL" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2009-07", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943072" }, { "nct_id": "NCT04740931", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Central Retinal Vein Occlusion", "Hemiretinal Vein Occlusion" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 729, "start_date": "2021-03-02", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 57, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740931" }, { "nct_id": "NCT03810313", "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Central Retinal Vein Occlusion" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2019-07-03", "completion_date": "2021-07-26", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03810313" }, { "nct_id": "NCT02245516", "title": "Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Retinal Vein Occlusion", "Diabetic Macular Edema" ], "interventions": [ { "name": "KPI-121 0.25% Ophthalmic Suspension", "type": "DRUG" }, { "name": "KPI-121 1.0% Ophthalmic Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kala Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 2, "location_summary": "Beverly Hills, California • Boston, Massachusetts", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02245516" }, { "nct_id": "NCT05850520", "title": "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema Secondary to Retinal Vein Occlusion" ], "interventions": [ { "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose", "type": "DRUG" }, { "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" }, { "name": "Fluorescein", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 892, "start_date": "2023-05-15", "completion_date": "2025-05-27", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 53, "location_summary": "Fullerton, California • Long Beach, California • Mountain View, California + 48 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05850520" }, { "nct_id": "NCT02698566", "title": "A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2016-03-21", "completion_date": "2016-04-05", "has_results": true, "last_update_posted_date": "2017-09-21", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 4, "location_summary": "Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more", "locations": [ { "city": "Paducah", "state": "Kentucky" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02698566" }, { "nct_id": "NCT04740905", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Branch Retinal Vein Occlusion" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 553, "start_date": "2021-03-02", "completion_date": "2023-06-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-06-10T04:07:40.281Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740905" } ] }